Ludaopei Hospital   Report issue

Academic/Hospital Phase 1 Phase 2
Founded: Beijing China (1964)

Organization Overview

First Clinical Trial
2017
NCT03312205
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Beijing Ludaopei Hospital | Beijing Lu Daopei Hospital | Hebei Yanda Ludaopei Hospital | HeiBei YanDa Ludaopei hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 1)

Cytomegalovirus Infections (Phase 1)

Infections (Phase 1)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Multiple Myeloma (Phase 1)

Neoplasm, Residual (Phase 1)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 32
  • # of Trial APIs: 22